COVID-19 impacts us all in unexpected ways - If you're still in the lab or working at home please let us know how we can help - Contact Us

Horizon Discovery offers CHOSOURCE™ platform for COVID-19-related therapeutics and diagnostics

14 Apr 2020 | Press release

  • Special licensing terms enable rapid access to CHOSOURCE platform to streamline SARS-CoV-2 therapeutic development and production processes
  • Supports global efforts to develop therapeutics, diagnostic assay components and vaccines to combat the COVID-19 Coronavirus pandemic 

Cambridge, UK, 14 April 2020: Horizon Discovery Group plc (LSE: HZD) (“Horizon”, “the Company” or “the Group”), a global leader in the application of gene editing and gene modulation for cell line engineering, today announced special commercial licensing terms to facilitate rapid access to its cGMP-compliant CHOSOURCE™ platform for the development or production of therapeutic proteins, diagnostic assay components or vaccines relating to COVID-19.

The CHOSOURCE platform includes a gene-edited Glutamine Synthetase (“GS”) knockout Chinese Hamster Ovary (CHO) K1 cell line, a well-established GS expression system recognized in the industry and by regulators as suitable for high yield biomanufacturing. The platform is already offered as a royalty-free alternative for the production of complex proteins and is empowering organizations from early stage start-ups to large pharmaceutical companies to drive efficiencies throughout development and production. CHOSOURCE has been utilized in multiple successful Innovative New Drug (IND) filings. 

Horizon is already a key supplier for research relating to COVID-19, providing many tools and services to academia and industry to support their efforts in addressing the pandemic. This offering further extends Horizon’s COVID-19 support portfolio: https://horizondiscovery.com/en/products/covid19-research-support

Jesús Zurdo, Global Head Bioprocessing, Horizon Discovery said:The current coronavirus crisis is highlighting existing shortcomings in the development of much-needed therapeutics. Horizon Discovery is fully committed to help innovators in their efforts to develop new solutions to tackle the COVID-19 pandemic. We are providing immediate access to our state-of-the-art bioproduction platform under very favorable terms to facilitate such efforts.” 

Terry Pizzie, CEO, Horizon Discovery said:We are committed to providing flexible, royalty-free access licensing terms and solutions that streamline development and production processes. Building upon more than a decade of experience in cell line engineering, we developed our CHOSOURCE cell line and now support a growing number of pharmaceutical companies in bioproduction. We are doing all that we can to support the fight against COVID-19 and hope that offering rapid access to our CHOSOURCE platform will help to accelerate the development and validation of new therapies to combat the pandemic.

For further information about Horizon’s CHOSOURCE platform for COVID-19, please contact bioproduction@horizondiscovery.com

 

ENDS

For a high res images please contact lorna.cuddon@zymecommunications.com
     
 Terry Pizzie, CEO, Horizon Discovery        Jesus Zurdo, Global Head Bioprocessing, Horizon Discovery

 

 

For further information from Horizon Discovery Group plc, please contact:


Zyme Communications (Trade and Regional Media)
Lorna Cuddon
Tel: +44 (0)7811 996 942
Email: lorna.cuddon@zymecommunications.com  


To opt-out from receiving press releases from Zyme Communications please email info@zymecommunications.com. To view our privacy policy, please click here.

About Horizon Discovery Group plc - horizondiscovery.com
Horizon Discovery Group plc (LSE: HZD) ("Horizon") drives the application of gene editing and gene modulation within the global life science market – supporting scientists on the path from research to therapy.

Built upon more than a decade of experience in the engineering of cell lines, Horizon offers an unmatched portfolio of tools and services to help scientists gain a greater understanding of gene function, identify genetic drivers behind human disease, deliver biotherapeutics, cellular and gene therapies for precision medicine as well as develop and validate diagnostic workflows. 

Horizon’s solutions enable almost any gene to be altered, or its function modulated, in human and other mammalian cell lines. 

The Company’s customers include many of the world’s foremost academic institutes, global pharmaceutical and biotechnology companies as well as clinical diagnostic laboratories. Insight into the challenges faced by these organizations enables the Company to focus efforts on development of innovative solutions that not only differentiate the Company’s offering, but also fuel development of the next wave of precision medicines. 

Horizon is headquartered in Cambridge, UK with offices in USA and Japan. The Group is listed on the London Stock Exchange's AIM market under the ticker HZD.

Follow Horizon Discovery on Twitter @HZDiscovery and LinkedIn @Horizon Discovery